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cross-sectional survey was conducted at the main referral hospitals in East Africa – 
Mulago, Uganda; Kenyatta, Kenya; Muhimbili, Tanzania; Center Hospitalier Universite 
de Kigali (CHUK), Rwanda; and CHUK, Burundi. Using a questionnaire based on the 
World Federation of the Societies of Anaesthesiologists (WFSA) guidelines for safe 
anaesthesia, we assessed demographic, administrative, peri-operative variables by 
interviewing anaesthetists in these hospitals, key informants from the Ministry 
of Health and National Anaesthesia Society of each country. Results: Using the 
WFSA checklist as a guide, only four percent of respondents were able to provide safe 
obstetric anaesthesia, and only seven percent reported adequate anaesthesia staffing. 
There were only 30 anaesthesiologists in Uganda, 168 in Kenya, 22 in Tanzania, 15 in 
Rwanda, and 2 in Burundi. Hospitals were barely equipped with monitors that some-
times were not functional. The paucity of local protocols, the failed referral system 
and lack of intensive care unit services was also reported to contribute significantly 
to poor maternal outcomes. ConClusions: We identified significant shortages of 
both personnel and equipment needed to provide safe anaesthetic care for obstetric 
surgical cases across East Africa. There is need to develop policies and strengthen 
the health systems in order to improve surgical outcomes in developing countries.
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objeCtives: Familial Chylomicronemia Syndrome (FCS) is a rare hereditary form of 
hyperchylomicronemia, a lipoprotein dysfunction leading to high levels of plasma 
triglycerides and resulting in various complications, including acute pancreatitis and 
abdominal pain. It affects about 1-2/1,000,000 individuals worldwide. The purpose 
of this study was to estimate the health care resource utilization, more specifically 
hospitalizations associated with FCS patients in a real-life setting. Methods: A ret-
rospective study was conducted using data from patients who were diagnosed with 
FCS at the Saguenay-Lac-St-Jean hospitals and clinics between January 1958 and 
April 2015. Patients were included in the database regardless of their age or the time 
since diagnosis. Data collection was performed from December 2014 to June 2015. 
Hospitalizations were confirmed by an exhaustive medical chart review. We focused 
on characteristics associated with FCS pancreatitis-related hospitalizations (PRH) and 
abdominal pain-related hospitalizations (APRH). Results: The study included 58 FCS 
patients (mean age of 43.9 years (SD= 15.1), 57.0% men). Thirty-one (53.0%) patients 
suffered from at least one episode of pancreatitis or from other abdominal pain, 
among which, 30 and 24 of these patients required at least 1 hospitalization because 
of PRH or APRH respectively. PRH were more frequent (15.7 hospitalizations/patient) 
than APRH (4.5 hospitalizations/patient). Furthermore, the PRH rate was higher in 
women than in men (19.9 hospitalizations/women vs. 12.0 hospitalizations/men). 
Moreover, pancreatitis and abdominal pain were associated with an average of length 
of hospital stay of 8.1 (SD= 8.5) and 6.5 (SD= 7.4) days respectively, and was higher 
in women than men for PRH (9.1 vs. 6.5 days) and for APRH (9.5 vs. 4.6 days). Based 
on the current average hospital cost per day in Quebec, Canada, estimated costs is 
CDN$7,970 per PRH and CDN$6,396 per APRH. ConClusions: FCS is associated with 
increased hospitalization resource utilization and cost. Pancreatitis and abdominal 
pain represent cost-generating complications.
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objeCtives: Sugammadex significantly reduces time and variability of recovery 
from neuromuscular blockade (NMB) compared to neostigmine. We explore potential 
impact on operating room (OR) efficiency and incidence of residual neuromuscular 
blockade (RNMB) with use of sugammadex versus neostigmine in Canada. Methods: 
A discrete event simulation (DES) model was developed to compare ORs using neostig-
mine and sugammadex for NMB reversal, for the same simulated schedule of proce-
dures. Selected inputs included OR procedure and turnover times, hospital policies 
with respect to paid staff overtime and procedural cancellations due to OR time 
over-run, and reductions in RNMB and associated complications with sugammadex 
use. Trials have shown that sugammadex’s impact on OR time and RNMB varies by 
whether full neuromuscular recovery (train-of-four [TOF] ratio ≥ 0.9) is verified prior 
to extubation in the OR. Two scenarios were therefore evaluated; when full recovery 
is verified prior to extubation and when it is not. Results: In the modeled scenario 
where full neuromuscular recovery was verified prior to extubation (92 procedures 
performed over one month with sugammadex), the use of sugammadex versus 
neostigmine over one month avoided 5.5 procedural cancellations and 9.3 hours of 
paid overtime, while saving an average of 61 minutes per OR day. No difference was 
observed between comparators for these endpoints in the modeled scenario when 
full neuromuscular recovery was not verified prior to extubation, however, the per 
procedure risk of RNMB at extubation was reduced from 60% to 4% (reflecting 48 
cases prevented over one month), with associated reductions in risks of hypoxemia 
(12 cases avoided) and upper airway obstruction (21 cases avoided). ConClusions: 
The impact of sugammadex was found to vary according to practices for neuromus-
cular recovery and extubation. Use of sugammadex can improve the current trade-off 
between OR efficiency and occurrence of RNMB when utilizing neostigmine.
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in European countries. In Poland and France the same, highest rate of reimbursed 
orphan drugs (19.4%) was observed. The lowest rate is in Scotland where only 1.1% of 
identified orphan drugs is reimbursed. The highest rate of reimbursed drugs is among 
drugs which obtained positive or conditional recommendation from HTA Agencies. 
Atypically, in Poland and Germany 45%-60% of drugs with negative recommendation 
is reimbursed from public funds. ConClusions: More than 75% of approved orphan 
drugs have been assessed by any of European HTA Agency, but only part of them (36%) 
are reimbursed from public funds. The reimbursement status not always corresponds 
with the type of HTA Agency recommendation in case of orphan drugs.
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objeCtives: Persistent opioid exposure is associated with increasing healthcare 
resource utilization and mortality. In last decade, there has been an increase in 
tramadol-related deaths in the U.K that may be related to persistent use of tramadol. 
However, there is a lack of consensus on defining the persistency of tramadol utilisa-
tion. This study aimed to explore the feasibility of applying definitions of persistent 
opioid utilisation to quantify the persistency of tramadol utilisation. Methods: This 
retrospective cohort study used the Clinical Practice Research Datalink. Patients who 
were prescribed tramadol from 2000 to 2011 were followed from the first tramadol 
prescription. Patients who were issued at least one tramadol prescription consecu-
tively in each follow-up patient year were defined as persistent users. The annual 
define daily dose (DDD) and number of supply day were calculated and stratified 
by persistent and non-persistent users. Descriptive statistic was used to report the 
proportion of persistent tramadol users consuming more than 180 DDD, 365 DDD and 
90 days of supply annually. Results: Overall, 526,624 tramadol users were identified, 
but 5460 (1%) tramadol users were persistently prescribed tramadol annually for 10 
years. The median and interquartile range (IQR) of annual DDD and number of supply 
day are 200 (IQR: 100, 330) DDD and 224 (IQR: 114, 327) days in persistent group, and 
45 (IQR: 17, 147) DDD and 51 (IQR: 16, 166) days in non-persistent group, respectively. 
For patients have been persistently prescribed tramadol annually for 10 years, 81% 
had annual number of supply day more than 90 days; however, only 45% and 19% had 
annual DDD more than 180 DDD and 365 DDD. ConClusions: The definitions of 
persistent opioid utilisation are not effectively in quantifying persistency of tramadol 
utilisation. Further study is needed to explore the association between persistent 
tramadol utilisation and clinical outcome and resource utilisation.
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objeCtives: This study aims to determine the level of consensus that exits amongst 
experts on the most likely actions to be implemented to enable equal access to 
Orphan Drugs (OD) and specialized care to Rare Disease (RD) patients’ in the public 
health sector in Spain. Methods: Two-round Delphi survey; RD experts identified 
by the study scientific committee. The questionnaire [32 statements related to OD 
price and reimbursement (n= 5); access to OD and specialized health care (n= 19); RD 
registry (n= 7); care model for RD (n= 1)] was based on a literature review and 2 focus 
groups. Agreement was sought on the desire (D) and prognosis (P) for each statement 
to occur over the next 5 year. Consensus was reached when 75% participants, or more, 
choose the totally or partially agreed options (agreement), or the totally or partially 
disagreed alternatives (disagreement). Descriptive statistics were applied. Results: 
82 experts (50.9% response rate) participated [clinicians (n= 41); hospital pharmacists 
(n= 16); health care managers (n= 13); patients (n= 9) and pharmaceuticals representa-
tives (n= 3)]. Agreement on D and P of occurrence was reached in 66.07% (n= 37) asser-
tions: reference teams will define referral protocols, treatment criteria and practice 
guidelines (D: 97.56%; P: 89.74%); a unified, etiology based RD registry will support 
clinical decision making (D: 97.56%; P: 84.62%). Divergence between D and P existed 
in 32.14% (n= 18) statements: OD reimbursement conditions will be reviewed every 5 
years based on clinical evidence (D: 90.24%; P: 74.36%); medical teams will network 
to coordinate RD patients’ care (D: 99%; P: 62%); home care teams will enable a more 
efficient care support to RD patients (D: 91%; P: 56%). ConClusions: Consensus 
was mostly reached on practical issues. RD experts are less optimistic about the 
immediate future of endeavors that require health care processes review to succeed 
in easing access to OD and specialized care for RD in Spain.
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objeCtives: The United Nations 2015 Millennium Development Goals targeted 75% 
reduction in maternal mortality. However in spite of this goal, the number of deaths 
per 100 000 live births remains unacceptably high across Sub-Saharan Africa. As many 
of these deaths could be averted with safe access to surgery including cesarean sec-
tions, the objective of this study was to assess the capacity to provide safe anaes-
thetic care for mothers in the main referral hospitals in East Africa. Methods: The 
